Skip to main content

Advertisement

SpringerLink
Log in

PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the use of [18F]fluorothymidine (FLT) as a positron emission tomography (PET) tracer for the diagnosis of breast cancer. To this end, 12 patients with 14 primary breast cancer lesions (T2–T4) were studied by FLT-PET. For comparison, [18F]fluorodeoxyglucose (FDG) PET scans were performed in six patients. Thirteen of the 14 primary tumours demonstrated focally increased FLT uptake (SUVmean=3.4±1.1). Seven out of eight patients with histologically proven axillary lymph node metastases showed focally increased FLT uptake in the corresponding areas (SUVmean=2.4±1.2). The lowest SUV (mean =0.7) was observed in one of two inflammatory cancers. The contrast between primary tumours or metastases and surrounding tissue was high in most cases. In direct comparison to FDG-PET, the SUVs of primary tumours (5/6) and axillary lymph node metastases (3/4) were lower in FLT-PET (SUVFLT: 3.2 vs SUVFDG: 4.7 in primary tumours and SUVFLT: 2.9 vs SUVFDG: 4.6 in lymph node metastases). Since FLT uptake in surrounding breast tissue was also lower, tumour contrast was comparable to that with FDG. It is of note that normal FLT uptake was very low in the mediastinum, resulting in a higher tumour-to-mediastinum ratio as compared to FDG (P=0.03). FLT-PET is suitable for the diagnosis of primary breast cancer and locoregional metastases. High image contrast may facilitate the detection of small foci, especially in the mediastinum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A, B
Fig. 2

References

  1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2:157–164.

    CAS  PubMed  Google Scholar 

  2. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, LawhornCrews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 1998; 4:1334–1336.

    Article  CAS  PubMed  Google Scholar 

  3. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43:1210–1217.

    CAS  PubMed  Google Scholar 

  4. Buck AK, Schirrmeister H, Hetzel M, von der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331–3334.

    CAS  PubMed  Google Scholar 

  5. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallieres E, Wood DE. In vivo validation of 3’deoxy-3’-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315–3323.

    CAS  PubMed  Google Scholar 

  6. Dohmen BM, Kuntzsch M, Dittmann H, Wei R, Eschmann SM, Machulla H-J, Bares R. FLT-Metabolismus beim Menschen: Konsequenzen für die [F-18]FLT-PET. Nuklearmedizin 2001; 39:V19.

    Google Scholar 

  7. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ, Bares R. [(18)F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407–1412.

    Article  CAS  PubMed  Google Scholar 

  8. Lu I, Samuelsson L, Bergstrom M, Sato M, Fasth KJ, Langstrom B. Rat studies comparing 11C-FMAU, 18-FLT, and 76Br-BFU as proliferation marker. J Nucl Med 2002; 43:1688–1698.

    CAS  PubMed  Google Scholar 

  9. Grierson JR, Vesselle H, Hofstrand P, Chin L, Rasey JS. Comparative uptake and cell cycle measurements with [F-18]FLT vs [H-3]thymidine in mammalian tumor cells. J Nucl Med 1998; 39:229P–230P.

    Google Scholar 

  10. Morabito A, Magnani E, Gion M, Sarmiento R, Capaccetti B, Longo R, Gattuso D, Gasparini G. Prognostic and predictive indicators in operable breast cancer. Clin Breast Cancer 2003; 3:381–390.

    PubMed  Google Scholar 

  11. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, Von Smitten K, Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1 N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9:923–930.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Clinic, Department of Gynecology and Obstetrics, University of Tübingen, 72076, Tübingen, Germany

    Brigitte Smyczek-Gargya, Nikos Fersis & Diethelm Wallwiener

  2. Department of Nuclear Medicine/PET-Center, University of Tübingen, Ottfried-Müller-Strasse 14, 72076, Tübingen, Germany

    Helmut Dittmann, Gerald Reischl, Hans-Juergen Machulla, Roland Bares & Bernhard M. Dohmen

  3. Department of Pathology, University of Tübingen, 72076, Tübingen, Germany

    Ulrich Vogel

Authors
  1. Brigitte Smyczek-Gargya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikos Fersis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helmut Dittmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulrich Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerald Reischl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans-Juergen Machulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Diethelm Wallwiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roland Bares
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bernhard M. Dohmen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmut Dittmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smyczek-Gargya, B., Fersis, N., Dittmann, H. et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31, 720–724 (2004). https://doi.org/10.1007/s00259-004-1462-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1462-8

Keywords

Search

Navigation